<DOC>
	<DOCNO>NCT01716559</DOCNO>
	<brief_summary>This observational , prospective , multicenter study evaluate treatment response rate safety NeoRecormon ( epoetin beta ) anemic patient non-myeloid malignancy . In addition NeoRecormon , patient receive chemotherapy malignancy . Data collect 16 week .</brief_summary>
	<brief_title>An Observational Study NeoRecormon ( Epoetin Beta ) Anemic Patients With Non-myeloid Malignancy</brief_title>
	<detailed_description />
	<criteria>Adult patient , &gt; /=18 year age Presence solidtumor nonmyeloid malignancy Patients receive chemotherapy Eastern Cooperative Oncology Group ( ECOG ) Performance status 02 Patients require NeoRecormon Hypersensitivity drug Uncontrolled hypertension Female patient pregnant and/or lactate</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2016</verification_date>
</DOC>